Capricor Therapeutics, Inc.
CAPR US
CAPR USCapricor Therapeutics, Inc.
United States Composite5.17
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.- Business
- Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation. The company was founded in 2005 and is headquartered in San Diego, California.
Company News
Pfizer Phase III DMD Gene Therapy Study Misses Goal
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
What's Going On With Capricor Therapeutics Stock Tuesday?
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway
Capricor Advances in DMD Therapy With Positive Study Data
Capricor (CAPR) Advances in DMD Therapy With Positive Study Data
What's Going On With Capricor Therapeutics Stock Tuesday?
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
Capricor Therapeutics (NASDAQ:CAPR) shareholder returns have been stellar, earning 113% in 5 years
Capricor Therapeutics stock rises, Oppenheimer initiates coverage at Outperform
Capricor Therapeutics: A Buy Rating Backed by Financial Stability and Promising DMD Treatment Developments
Analysts’ Top Healthcare Picks: Stereotaxis (STXS), Capricor Therapeutics (CAPR)
Capricor Therapeutics: A Strong Buy on Positive Financial Outlook and Regulatory Advancements
Capricor Therapeutics Inc (CAPR) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Capricor Therapeutics Inc (CAPR) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress and Financial Insights
Q1 2024 Capricor Therapeutics Inc Earnings Call Transcript
Capricor Therapeutics (CAPR) Reports Q1 Loss, Misses Revenue Estimates
Capricor Therapeutics (CAPR) Reports Q1 Loss, Misses Revenue Estimates
Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update